As we found DLK1 to be expressed in a subset of metastatic cancers apart from ACC (Fig. 1A), we hypothesized that ADCT-701 would be highly effective against DLK1+ tumors with low or no ABCB1 expression, such as SCLC. Here, DLK1 is linked to metastatic malignant neoplasm.